Ying Jin

Harbin Medical University — China

Medicine · Health Sciences

47h-index7.6kcitations261works10.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(53), Colorectal Cancer Treatments and Studies(39), Lung Cancer Research Studies(38), Cancer Genomics and Diagnostics(35), Gastric Cancer Management and Outcomes(32)

Publications261 total

A cell-specific computational framework reveals a pan-cancer hypoxia signature predicting overall survival and ICI response
Journal of Biological Chemistry·2025Open Access
TET2 repression contributes to EGFR TKI resistance in EGFR-mutant non-small cell lung cancer through regulating AXIN2 methylation
Scientific Reports·2025Open Access
Low-dose simvastatin protects pancreatic cancer cells by promoting mitochondrial autophagy through TFEB
2025Open Access
Data from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
2025· 1 citedOpen Access
Supplementary Figure S3 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
2025Open Access
Supplementary Figure S5 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
2025Open Access
Supplementary Figure S4 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
2025Open Access
Supplementary Figure S10 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
2025Open Access
Supplementary Figure S9 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
2025Open Access
Supplementary Figure S8 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
2025Open Access
Supplementary Figure S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
2025Open Access
Supplementary Video S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
2025Open Access
Supplementary Figure S6 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
2025Open Access
Supplementary Video S1 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
2025Open Access
Supplementary Figure S7 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
2025Open Access
Supplementary Figure S1 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
2025Open Access
Supplementary Figure S11 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
2025Open Access
Supplementary Table 1-4 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors
2025Open Access
A de novo mutation in RAB11A is associated with neurodevelopmental disorder accompanied by variable multisystem abnormalities
Frontiers in Genetics·2025Open Access
Development and Validation of a Nomogram for Prognostic Prediction in Ovarian Cancer Based on Tumor Proliferation and Immune-Related Biomarkers in Chinese Patients
International Journal of Women s Health·2025Open Access
page 1 of 14Next →

Frequent Co-authors

Rui‐Hua Xu(25), Zixian Wang(11), Yuhong Li(11), Feng Wang(10), Hui Luo(10), Feng‐Hua Wang(10), Miao‐Zhen Qiu(10), De‐Shen Wang(9), Qi Zhao(7), Ming-Ming He(7), Chao Ren(6), Zhi‐Qiang Wang(6), Zexian Liu(5), Huai‐Qiang Ju(4), Jibin Li(4), Dongsheng Zhang(4), Wen‐Long Guan(4), Xinmin Yu(4), Ming Chen(4), Xun Shi(4)